Sharing many of the data challenges and opportunities faced by Healthcare, the Life Sciences industry remains focused on delivering new, innovative therapies and solutions to patients in a cost effective, timely and safe way. With spiraling R&D costs, new methods such as adaptive trials, and never ending need for deep pharmacovigilance, the Life Sciences companies that effectively use analytics to explore, monitor and optimize their business will rapidly become the new leaders.

Oracle’s strategy—built upon Enterprise Health Analytics and Health Data Warehouse Foundation—provides a powerful, practical, and extensible approach to delivering the IT analytics infrastructure required to confront the worldwide healthcare challenge.

Business Process Management (BPM) software offers liberation in the planning and management of clinical trials today. SmartBPM provides the components for automating critical clinical trial processes ranging from protocol development and patient enrollment to site management and investigator payments. Advantages are:

• Potentially stunning return on investment at multiple levels.
• A 500%, or better, increase in application development time by directly executing business requirements
• Improved customer retention
• A 50% possible reduction in training time

Discovered is opportunity to enhance relationships with investigators, subjects, and regulators while bringing momentum to a technology-impaired study startup phase. Learn more about SmartBPM in this complimentary white paper.

New technologies are available to leverage Cloud Computing in  managing clinical trial data. This paper discusses a next generation eClinical
platform that:

• Speeds trial set up
• Accommodates changes with zero downtime
• Integrates effectively with other clinical trial technology systems

It is offered with either software-as-a-service (SaaS), or turnkey infrastructure options in which the user organization operates their own cloud using their IT teams, within their data centers. Read this paper to learn and decide how best to leverage cloud computing’s many strengths for your organization’s  particular needs.

To effectively and efficiently manage the rapidly increasing needs of an NGS research environment numerous considerations for data management become important in moving today’s terabyte and petabyte levels of data. Some key concerns can include:

• Maintaining enough  headroom to handle additional and unplanned data growth
• How to address mixed workloads
• Working with multiple file and network protocols
• Dealing with aging data
• Optimizing varied storage subsystems already in place while preparing for new floods of data to come

This paper investigates trends and solutions in addressing these issues, and more, for life science professionals.

In this Briefing On special report, Bio-IT World’s editorial team presents a selection of stories published in the past 12-24 months examining the technologies that are both creating and solving the next-gen data deluge. From the point of data generation and extending through data management, access, analysis, collaboration and storage, you should find a range of interesting and useful articles intended to help with technology decision making processes inside of your organization.

Facing pipeline difficulties, increasing costs and timeline pressures, more biopharmaceutical companies are looking into standards as a tool for data integration and analysis leading to better decisions. Standards operate in a highly complex environment, are somewhat immature, and are continuing to evolve.  Presently, even the most progressive adopters face hurdles in implementing standards, but there is an effective strategy for moving forward as discussed in this complimentary white paper which includes:

• Laying out guiding principles for improving standards implementation
• Identifying challenges
• Technology solutions used in creating data transparency, and organizational value

The legal protection of research-based intellectual property (IP) data in lab management systems and workflows is paramount.  Improper IP controls can endanger ownership, revenue and potentially an entire business for years if time of creation (“first-to-invent”) and authenticity aren’t proven. This article is a reprint of an actual case study. It discusses how a leading pharmaceutical company protected assets by:

• Integrating simple; long-term and cost-effective automated controls to protect scientific IP.
• Automating tasks scientists followed to “sign and witness” volumes of research records for legal purposes. 
• Protecting against lost IP claims, rejected patents, and ultimately lost revenue.